Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Phase 3positiveVYEPTIPositive

AI Analysis

Summary

Lundbeck announced positive Phase IV THRIVE trial results for VYEPTI (eptinezumab), with 60% of patients reporting significant improvement in migraine following treatment after inadequate response to prior CGRP-targeting preventive therapy.

Clinical Trial Data

Phase

Phase IV

Primary Endpoint

Met

Outcome Details

60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab

Importance:6/10

Sentiment:

0.70

eptinezumabVYEPTImigraineCGRPpreventive therapyPhase IV

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on October 1, 2026 6:17 AM

Read Original